The company's shares jumped 10 percent on the positive datafor its lead drug, ATX-101.

Over 1000 patients with moderate to severe submental fatwere tested in the two studies conducted in the United Statesand Canada, where ATX-101 was evaluated against a placebo.Submental fat is concentrated in the area under the chin.

If approved, the drug could fulfill an unmet medical need asthere is no proven non-surgical option to effectively reducesubmental fat, said Dr Jean Carruthers, one of the investigatorsof Kythera's clinical study.

The most common adverse events were swelling, pain,bruising, numbness and redness, but none were treatment-related,Kythera said.

Kythera, which focuses on making aesthetic medicines, willdisclose additional data from the two studies at the AmericanSociety for Dermatologic Surgery meeting between Oct. 3-6.

The company has said it plans to assess future potentialtreatments for ATX-101 in the body.

Germany's Bayer AG holds development andmarketing rights to ATX-101 outside the United States andCanada.

Shares of Calabasas, California-based Kythera rose to $36.98in after-market trading. The stock closed at $33.53 on theNasdaq on Monday.